Instil Bio, Inc.
HealthcareNASDAQ:TIL · NASDAQ Global Select
-$0.01 today
Vol 0.01M · Avg 0.03M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-62.7%
avg -51.2%
ROIC
-26.6%
avg -38.7%
ROA
-35.1%
avg -37.6%
Analysis
ROIC is currently the strongest return metric at -26.6% versus its period average of -38.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Bronson Crouch | Chairman & Chief Executive Officer | $1.18M | — | 53 | $105,157.00 | 1.55% |
Sandeep Laumas | Chief Financial Officer & Chief Business Officer | $775,556.00 | — | 57 | $30,000.00 | 0.44% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
2
$701,667.24
Net Sentiment
$701,667.24
Net selling
Most Active
Laumas Sandeep
2 transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| Sep 10, 2025 | Laumas Sandeep Direct | Sell | 17.5K | $23.04 | $404,098.56 | |
| Sep 10, 2025 | Laumas Sandeep Direct | Sell | 12.5K | $23.88 | $297,568.68 |
Analysis
Insiders reported 0 buys worth $0.00 and 2 sells worth $701,667.24 over the last 12 months. That adds up to net selling of $701,667.24. Laumas Sandeep was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A0 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTL
$266.95M
MacroGenics, Inc.
NASDAQ:MGNX
$251.71M
Shattuck Labs, Inc.
NASDAQ:STTK
$236.64M
Whitehawk Therapeutics Inc
NASDAQ:WHWK
$205.72M
Surrozen, Inc.
NASDAQ:SRZN
$174.90M
InflaRx N.V.
NASDAQ:IFRX
$115.57M
Oncolytics Biotech Inc.
NASDAQ:ONCY
$80.59M
Pliant Therapeutics, Inc.
NASDAQ:PLRX
$69.97M
Tevogen Bio Holdings Inc.
TVGN
$43.84M
Atossa Therapeutics, Inc.
ATOS
$21.18M
Who manages TIL?
Instil Bio, Inc. (TIL) lists 2 active executives. The top listed executive is Sandeep Laumas, Chief Financial Officer & Chief Business Officer.
Are TIL insiders buying or selling?
Recent insider activity shows net buying of $91.57M.
Explore More
Continue the stock analysis
Jump to another research area for this company.